


## PF-07284892

<b>Cat. No.:</b>	HY-153740		
<b>CAS No.:</b>	2498597-94-5		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>22</sub> ClN <sub>7</sub> S		
<b>Molecular Weight:</b>	439.96		
<b>Target:</b>	SHP2		
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (227.29 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.2729 mL	11.3647 mL	22.7293 mL
		5 mM	0.4546 mL	2.2729 mL	4.5459 mL
10 mM		0.2273 mL	1.1365 mL	2.2729 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: 2.5 mg/mL (5.68 mM); Clear solution; Need ultrasonic</li> </ol>				

### BIOLOGICAL ACTIVITY

<b>Description</b>	PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC <sub>50</sub> value of 21 nM. PF-07284892 decreases the expression of pERK <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 21 nM (SHP2) <sup>[1]</sup>
<b>In Vitro</b>	PF-07284892 (100 nM; 4, 18 h) combines with lorlatinib (0-450 nM), binimetinib (0-160 nM) decreases the expression of pERK in H3122 lorR-06, VACO-432 cells <sup>[2]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**

PF-07284892 (10 mg/kg; p.o.) shows good oral bioavailability with F% of 85%, 94%, 102%, 64% for mouse, rat, dog, monkey, respectively<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**REFERENCES**

[1]. Abdayem P, et al. Ongoing progress in BRAF-mutated non-small cell lung cancer. Clin Adv Hematol Oncol. 2022 Nov;20(11):662-672.

[2]. Drilon A, et al. SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy. Cancer Discov. 2023 Jun 3:OF1-OF13.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA